Abstract:Annually, swine influenza A virus (SwIAV) causes severe economic loss to swine industry. Currently used inactivated SwIAV vaccines administered by intramuscular injection provide homologous protection, but limited heterologous protection against constantly evolving field viruses, attributable to the induction of inadequate levels of mucosal IgA and cellular immune responses in the respiratory tract. A novel vaccine delivery platform using mucoadhesive chitosan nanoparticles (CNPs) administered through intranasal (IN) route has the potential to elicit strong mucosal and systemic immune responses in pigs. In this study, we evaluated the immune responses and cross-protective efficacy of IN chitosan encapsulated inactivated SwIAV vaccine in pigs. Killed SwIAV H1N2 (δ-lineage) antigens (KAg) were encapsulated in chitosan polymer-based nanoparticles (CNPs-KAg). The candidate vaccine was administered twice IN as mist to nursery pigs. Vaccinates and controls were then challenged with a zoonotic and virulent heterologous SwIAV H1N1 (γ-lineage). Pigs vaccinated with CNPs-KAg exhibited an enhanced IgG serum antibody and mucosal secretory IgA antibody responses in nasal swabs, bronchoalveolar lavage (BAL) fluids, and lung lysates that were reactive against homologous (H1N2), heterologous (H1N1), and heterosubtypic (H3N2) influenza A virus strains. Prior to challenge, an increased frequency of cytotoxic T lymphocytes, antigen-specific lymphocyte proliferation, and recall IFN-γ secretion by restimulated peripheral blood mononuclear cells in CNPs-KAg compared to control KAg vaccinates were observed. In CNPs-KAg vaccinated pigs challenged with heterologous virus reduced severity of macroscopic and microscopic influenza-associated pulmonary lesions were observed. Importantly, the infectious SwIAV titers in nasal swabs [days post-challenge (DPC) 4] and BAL fluid (DPC 6) were significantly (<i>p</i> < 0.05) reduced in CNPs-KAg vaccinates but not in KAg vaccinates when compared to the unvaccinated challenge controls. As well, an increased frequency of T helper memory cells and increased levels of recall IFNγ secretion by tracheobronchial lymph nodes cells were observed. In summary, chitosan SwIAV nanovaccine delivered by IN route elicited strong cross-reactive mucosal IgA and cellular immune responses in the respiratory tract that resulted in a reduced nasal viral shedding and lung virus titers in pigs. Thus, chitosan-based influenza nanovaccine may be an ideal candidate vaccine for use in pigs, and pig is a useful animal model for preclinical testing of particulate IN human influenza vaccines.

Chitosan Microspheres Containing Bordetella Bronchiseptica Antigens As Novel Vaccine Against Atrophic Rhinitis in Pigs

Pluronic® F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin

In Vitro Study of the Immune Stimulating Activity of an Athrophic Rhinitis Vaccine Associated to Chitosan Microspheres

Immune Stimulating Activity of an Atrophic Rhinitis Vaccine Associated to Pegylated Chitosan Microspheres in Vitro

Aroa Deleted Bordetella Bronchiseptica Inspiring Robust Mucosal Immune Response and Provide Full Protection Against Intranasal Challenge

Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs

Immunogenicity of Recombinant Protective Antigen and Efficacy Against Intranasal Challenge with Bordetella Bronchiseptica

Nasal delivery of chitosan/alginate nanoparticle encapsulated bee (Apis mellifera) venom promotes antibody production and viral clearance during porcine reproductive and respiratory syndrome virus infection by modulating T cell related responses

Effects of Intranasal Administration with Bacillus Subtilis on Immune Cells in the Nasal Mucosa and Tonsils of Piglets

Co-administration of Attenuated Mycoplasma Hyopneumoniae 168 Strain with Bacterial DNA Enhances the Local and Systemic Immune Response after Intranasal Vaccination in Pigs.

The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization.

Intranasal Bovine Β-Defensin-5 Enhances Antituberculosis Immunity in a Mouse Model by a Novel Protein-Based Respiratory Mucosal Vaccine

An Innovative Approach to Induce Cross-Protective Immunity Against Porcine Reproductive and Respiratory Syndrome Virus in the Lungs of Pigs Through Adjuvanted Nanotechnology-Based Vaccination

Enhancing effect of chitosan nanoparticles on the immune efficacy of Bordetella bronchiseptica outer membrane vesicles

Controlled Release Ofbordetella Bronchiseptica Dermonecrotoxin (BBD) Vaccine from BBD-loaded Chitosan Microspheresin Vitro

Experimentary study of Dermatophagoides farinae-chitosan particles as a novel nasal delivery system for anti-antigen vaccine

Mucosal and systemic immune responses induced by intranasal immunization of recombinant Bacillus subtilis expressing P97R1, P46 antigens of Mycoplasma hyopneumoniae .

Pulmonary Application of Novel Antigen-Loaded Chitosan Nano-Particles Co-Administered with the Mucosal Adjuvant C-Di-AMP Resulted in Enhanced Immune Stimulation and Dose Sparing Capacity

Intranasal Vaccination with Mannosylated Chitosan Formulated DNA Vaccine Enables Robust IgA and Cellular Response Induction in the Lungs of Mice and Improves Protection Against Pulmonary Mycobacterial Challenge.

Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.

Quaternized chitosan nanoparticles loaded with the combined attenuated live vaccine against Newcastle disease and infectious bronchitis elicit immune response in chicken after intranasal administration